11th Advanced Forum on

Biotech Patents

Comprehensive & Practical Biotech Patent Prosecution and Litigation Strategies for an Evolving Legal Climate

Wednesday, September 30, 2009

About

Come to the one forum that will help you revise your strategies to adapt to new industry standards.

Emerging from a turbulent year of new case law, a resurgence of the proposed PTO rules, uncertainty associated with a new administration, and tough economic conditions, biotech patent practitioners must prepare for a new phase in this ever-evolving field. And with groundbreaking legislation regarding patent reform and follow-on biologics on the horizon, patent counsel must rise to the challenge to overcome increasing rejections, promote innovation and maximize profitability.

With this in mind, ACI’s 11th Advanced Forum on Biotech Patents once again brings together a high-caliber team of experienced biotech patent counsel who will share their collective knowledge and provide you with the most up to date strategies you can immediately incorporate into your practice.

Dedicated to the unique challenges faced by the biotech industry, your expert faculty will uncover critical insights involving:

  • Developing a practical approach to follow-on biologics
  • Preparing for the rule changes rising out of the Tafas decision
  • Strategically avoiding rejection in diagnostic, method of treatment, and method of screening claims
  • Delving into techniques to defeat charges of inequitable conduct
  • Insights into key rule changes in foreign patent offices, including a special presentation on the EPO and EU patent litigation
  • Overcoming challenges to antibody patent prosecution

Add value to your experience by attending our highly successful, interactive and in-depth Master Class on Drafting Successful Patent Applications for Biotechnology Inventions where you will learn how to master the art of drafting complex patent applications for your biotech inventions.


Contents & Contributors

About

Come to the one forum that will help you revise your strategies to adapt to new industry standards.

Emerging from a turbulent year of new case law, a resurgence of the proposed PTO rules, uncertainty associated with a new administration, and tough economic conditions, biotech patent practitioners must prepare for a new phase in this ever-evolving field. And with groundbreaking legislation regarding patent reform and follow-on biologics on the horizon, patent counsel must rise to the challenge to overcome increasing rejections, promote innovation and maximize profitability.

With this in mind, ACI’s 11th Advanced Forum on Biotech Patents once again brings together a high-caliber team of experienced biotech patent counsel who will share their collective knowledge and provide you with the most up to date strategies you can immediately incorporate into your practice.

Dedicated to the unique challenges faced by the biotech industry, your expert faculty will uncover critical insights involving:

  • Developing a practical approach to follow-on biologics
  • Preparing for the rule changes rising out of the Tafas decision
  • Strategically avoiding rejection in diagnostic, method of treatment, and method of screening claims
  • Delving into techniques to defeat charges of inequitable conduct
  • Insights into key rule changes in foreign patent offices, including a special presentation on the EPO and EU patent litigation
  • Overcoming challenges to antibody patent prosecution

Add value to your experience by attending our highly successful, interactive and in-depth Master Class on Drafting Successful Patent Applications for Biotechnology Inventions where you will learn how to master the art of drafting complex patent applications for your biotech inventions.


Contents & Contributors

Prepairing for the Inevitable Enactment of Follow-on Biologics Legislation and Adopting a Practical Approach to Integrating FOB's into your Patent Strategies
Maggie Shafmaster, Ph.D., Sr. Vice President, Chief Patent Counsel, Genzyme Corp. (Cambridge, MA)
Barbara A. Fiacco, Partner, Foley Hoag LLP (Boston, MA)
Jeffrey P. Kushan, Partner, Sidley Austin LLP (Washington, D.C.)

Politics and Patents: Reassessing your Patent Strategy in Light of Current Changes
Michele Cimbala, Ph.D., Director, Sterne Kessler Goldstein & Fox PLLC (Washington, D.C.)
Harold C. Wegner, Partner, Foley & Lardner LLP (Washington, D.C.)

What's patentable? The Impact of Bilski and Related Precedents to Diagnostic Testing & Treatment Claims in the Biotech Patent Industry
Warren D. Woessner, J.D., Ph.D., Founding Shareholder, Schwegman Lundberg & Woessner (Minneapolis, MN)
Stephen Albainy-Jenei, Member, Frost Brown Todd LLC (Cincinnati, OH)
Kevin E. Noonan, Ph.D., Partner, McDonnell Boehnen Hulbert & Berghoff LLP, (Chicago, IL)

Deciphering the Impact of In re Kubin on Application of §103 Obviousness Requirements

K. Shannon Mrksich, Ph.D., Shareholder, Chair of Biotech Practice Group, Brinks Hofer Gilson & Lione (Chicago, IL)
Janis K. Fraser, Ph.D., Principal, Fish & Richardson P.C. (Boston, MA)

Strategies for Patenting Biotechnology Inventions with Evolving §112 Jurisprudence
Anne Brown, Ph.D., Partner, Thompson Hine LLP (Cleveland, OH)
Jennifer Gordon, Ph.D., Partner, Baker Botts LLP (New York, NY)

Cultivating Proactive Prosecution Strategies to Overcome Charges of Inequitable Conduct
Michael K. Levy, Partner, Kenyon & Kenyon LLP (New York, NY)
William C. Coppola, Head – Patent Prosecution, Bio-genomics, Sanofi-Aventis, (Union, NJ)

Developing Global Biotech Patent Strategies and Indentifying Key Rule Changes in Foreign Patent Offices
Lesley Rapaport MSc., LL.B., Associate Chair,Vancouver Biotechnology Practice Group, Borden Ladner Gervais LLP (Vancouver, Canada)
Elizabeth N. Spar, Associate, Edwards, Angell, Palmer & Dodge LLP, (Boston, MA)

Spotlight Presentation: European Biotech Patent Law
Adrian Tombling, European and UK Patent Attorney, Withers & Rogers LLP, (London, UK)
Marjan Noor, Partner, Howrey (London, UK)

Tactics for Breaking Through the Challenges Associated with Antibody Patent Prosecution
Len Smith, Senior Intellectual Property Counsel, Novo Nordisk (Princeton, NJ)
Dr. Hans-Rainer Jaenichen, European Patent Attorney, Vossius & Partner, (Munich, Germany)


DOCUMENT TYPES: PPT PPTX PRESENTATIONS AVAILABLE: 16

8:00
Registration and Continental Breakfast
9:00
Co-Chairs' Opening Remarks
Immac J. Thampoe, Ph.D.
Senior Director-Patent Law
Schering-Plough Corporation
-Brian Coggio
Senior Principal
Fish & Richardson‚ P.C.
9:10
Prepairing for the Inevitable Enactment of Follow-on Biologics Legislation and Adopting a Practical Approach to Integrating FOB's into your Patent Strategies
Dr. Maggie Shafmaster
Vice President, Chief Patent Counsel
Sanofi Pasteur
1 file
Preparing for the Inevitable – Follow on Biologicst
1.2 MB 18 pages Presentation
PPT - Preparing for the Inevitable – Follow on Biologicst
Barbara A. Fiacco
Partner
Foley Hoag LLP
1 file
Preparing for the Inevitable – Follow on Biologicst
1.2 MB 18 pages Presentation
PPT - Preparing for the Inevitable – Follow on Biologicst
Mr. Jeffrey Kushan
Partner
Sidley Austin LLP
1 file
Preparing for the Inevitable – Follow on Biologicst
1.2 MB 18 pages Presentation
PPT - Preparing for the Inevitable – Follow on Biologicst
10:45
Politics and Patents: Reassessing your Patent Strategy in Light of Current Changes
Dr. Michele Cimbala
Director‚ Intellectual Property
Sterne‚ Kessler‚ Goldstein & Fox P.L.L.C.
1 file
American Conference Institute: 11 Advanced Forum on Biotech Patents Politics and Patents: Reassessing Your Patent Strategy in Light of Current Changes
2.7 MB 66 pages Presentation
PPT - American Conference Institute: 11 Advanced Forum on Biotech PatentsPolitics and Patents: Reassessing Your Patent Strategy in Light of Current Changes
Mr. Harold C. Wegner
Partner
Foley & Lardner LLC
1 file
Inter Partes Patent Reexamination: Challenges with Parallel Litigation
209.2 KB 59 pages Presentation
PPTX - Inter Partes  Patent Reexamination: Challenges with Parallel Litigation
12:00
Networking Luncheon
13:15
Uncovering Current Trends and Predicting Future Changes Facing Biotech Patent Practitioners
Thomas J. Filarski
Partner
Steptoe & Johnson LLP
Ms. Mary C. Till
Senior Legal Advisor, Office of Patent Legal Administration
United States Patent and Trademark Office
14:00
What's patentable? The Impact of Bilski and Related Precedents to Diagnostic Testing & Treatment Claims in the Biotech Patent Industry
Dr. Warren D. Woessner
Founding Shareholder
Scewgman Lundberg & Woessner
1 file
What’s Patentable? Method-of-Treatment and Mechanism-of-Action Claims.
234.5 KB 29 pages Presentation
PPT - What’s Patentable?  Method-of-Treatment and Mechanism-of-Action Claims.
Mr. Stephen Albainy-Jenei
Member
Frost‚ Brown‚ Todd‚ LLC
1 file
What’s Patentable? Emerging precedents
1.1 MB 32 pages Presentation
PPT - What’s Patentable? Emerging precedents
Dr. Kevin E. Noonan
Partner
McDonnell Boehnen Hulbert & Berghoff LLP
1 file
Bilski: A potential tragedy in 3 acts
399.5 KB 31 pages Presentation
PPT - Bilski:A potential tragedy in 3 acts
15:00
Afternoon Refreshment Break
15:15
Deciphering the Impact of In re Kubin on Application of §103 Obviousness Requirements
K. Shannon Mrksich, Esq.
Shareholder
Brinks Hofer Gilson & Lione
1 file
Deciphering In re Kubin
329.5 KB 51 pages Presentation
PPT - Deciphering  In re Kubin
Janis K. Fraser, Ph.D.
Principal
Fish and Richardson&sbquo P.C.
1 file
Deciphering In re Kubin
329.5 KB 51 pages Presentation
PPT - Deciphering  In re Kubin
16:15
Strategies for Patenting Biotechnology Inventions with Evolving §112 Jurisprudence
Anne Brown, Ph.D.
Partner
Thompson Hine LLP
1 file
Written Description Requirement: Biotechnology Inventions
438.5 KB 47 pages Presentation
PPT - Written Description Requirement: Biotechnology Inventions
Dr. Jennifer Gordon
Partner
Baker Botts LLP
1 file
Is This the Dawning of a New Age of Enablement?
305 KB 21 pages Presentation
PPT - Is This the Dawning of a New Age of Enablement?
17:15
Conference Adjourns for the Day
8:30
Continental Breakfast
9:00
Co-Chairs' Remarks
9:10
Cultivating Proactive Prosecution Strategies to Overcome Charges of Inequitable Conduct
Dr. Mark I. Levy
Medical Director, Assistant Clinical Professor Psychiatry
UCSF
William C. Coppola
Senior Patent Counsel
Sanofi-Aventis
1 file
Cultivating Proactive Prosecution Strategies to Overcome Charges of Inequitable Conduct
235.5 KB 41 pages Presentation
PPT - Cultivating Proactive Prosecution Strategies to Overcome Charges of Inequitable Conduct
10:15
Morning Coffee Break
10:30
Developing Global Biotech Patent Strategies and Indentifying Key Rule Changes in Foreign Patent Offices
Ms. Lesley Rapaport
Principal
LRR Patent Law
1 file
Global Biotech Patent Strategies and Key Changes - Canada
659.5 KB 35 pages Presentation
PPT - Global Biotech Patent Strategiesand Key Changes - Canada
Dr. Elizabeth N. Spar
Senior Associate
Edwards‚ Angell‚ Palmer‚ & Dodge LLP
1 file
Developing Global Biotech Patent Strategies and Identifying Key Rule Changes in Foreign Patent Offices
1.6 MB 22 pages Presentation
PPT - Developing Global Biotech Patent Strategies and Identifying Key Rule Changes in Foreign Patent Offices
11:30
Spotlight Presentation: European Biotech Patent Law
Mr. Adrian Tombling
Patent Attorney
Withers & Rogers LLP
1 file
Significant Changes in EPO Practice
638 KB 23 pages Presentation
PPT - Significant Changes in EPO Practice
Ms. Marjan Noor
Partner
Simmons & Simmons LLP
1 file
European Biotech Patent Law
409 KB 22 pages Presentation
PPT - European Biotech Patent Law
12:30
Networking Luncheon
14:00
Tactics for Breaking Through the Challenges Associated with Antibody Patent Prosecution
-Mr. Len S. Smith
Principal Intellectual Property Counsel
Medicis Pharmaceutical Corporation
1 file
Antibody Patenting Strategies
882 KB 20 pages Presentation
PPT - Antibody Patenting Strategies
Dr. Hans-Rainer Jaenichen
Patent Attorney
Vossius & Partner
1 file
THE PATENTING OF ANTIBODIES AND THEIR MEDICAL USES IN THE EPO
5.3 MB 96 pages Presentation
PPT - THE PATENTING OF ANTIBODIES AND THEIR MEDICAL USES IN THE EPO
Jane T. Gunnison
Partner
Ropes & Gray LLP
15:00
Afternoon Refreshment Break
15:15
Freedom to Operate Assessments for the Biotech Industry
Ms. Robin M. Silva
Partner
Morgan‚ Lewis‚ and Bockius LLP
16:15
Conference Adjourns